Linda Frisk, PharmD: Biosimilars and Cost Reduction

Linda Frisk, PharmD, of Arizona Oncology, discusses biosimilars and cost savings.


What is your understanding of the use of biosimilars at your practice?

Well there’s not too many biosimilars out right now. I do believe that there is a cost advantage to them, and I haven’t seen any difference in efficacy with the 1 that we’re currently using now. I am very much looking forward to that; I think that it will reduce cost and that’s what we need to do.